Sino Biological US, Inc. has unveiled ProPure™, a pioneering line of ultra-pure, endotoxin-free recombinant proteins, manufactured at its Center for Bioprocessing (C4B) in Houston, Texas. This development is set to transform immunology research, vaccine development, and therapeutic protein manufacturing by offering proteins with endotoxin levels below the limit of quantification, ensuring exceptional purity and safety for critical applications.
Dr. Rob Burgess, Chief Business Officer at Sino Biological US, highlighted the company's focus on scientific excellence and product safety, noting that ProPure™ proteins are crafted to adhere to the highest quality and consistency standards. The C4B facility's use of mammalian expression systems and proprietary purification techniques facilitates the production of proteins essential for advancing both fundamental and translational science.
The launch of ProPure™ underscores Sino Biological's dedication to bioprocessing innovation and its contribution to the global life sciences sector. In addition to its standard product line, the C4B facility provides tailored protein development services, addressing the specific requirements of researchers and biomanufacturers. This initiative highlights the critical role of high-quality, endotoxin-free proteins in fostering scientific discoveries and improving patient safety in therapeutic applications.
